Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab, Nivolumab, and Cryoablation in Advanced Melanoma
NCT05779423Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2023
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in melanoma, sponsored by Massachusetts General Hospital. Primary endpoint: Rate of Clinical Benefit at 6 months. Started Sep 2023; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05779423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05779423.